Enantiodivergent syntheses of (R)- and (S)- 3,5-dimethylcyclohex-2-en-1- ones from (R)-pulegone

Article abstract of DOI:10.1080/00397919408010206

R-(+)-pulegone (1) is transformed to (R)-5-methyl-2- (phenylsulfinyl)cyclohexanone (5) (65%, 3 steps). Sulfoxide 5 is converted to R-(-)-3,5-dimethylcyclohex-2-en-1-one (4) (53%, 4 steps) and S-(+)-4 (26%, 3 steps).

Full text of DOI:10.1080/00397919408010206

This article was downloaded by: [171.67.34.205]
On: 01 March 2013, At: 06:06
Publisher: Taylor & Francis
Informa Ltd Registered in England and Wales Registered Number: 1072954
Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH,
UK
Synthetic Communications: An
International Journal for Rapid
Communication of Synthetic
Organic Chemistry
Publication details, including instructions for
authors and subscription information:
http://www.tandfonline.com/loi/lsyc20
Enantiodivergent Syntheses
of (R)- and (S)-3,5-
Dimethylcyclohex-2-en-1-ones
from (R)-Pulegone
A. Nangia a & G. Prasuna a
a School of Chemistry, University of Hyderabad,
Hyderabad, 500 134, INDIA
Version of record first published: 23 Sep 2006.
To cite this article: A. Nangia & G. Prasuna (1994): Enantiodivergent Syntheses
of (R)- and (S)-3,5-Dimethylcyclohex-2-en-1-ones from (R)-Pulegone, Synthetic
Communications: An International Journal for Rapid Communication of Synthetic
Organic Chemistry, 24:14, 1989-1998
To link to this article: http://dx.doi.org/10.1080/00397919408010206
PLEASE SCROLL DOWN FOR ARTICLE
Full terms and conditions of use: http://www.tandfonline.com/page/terms-
and-conditions
This article may be used for research, teaching, and private study purposes.
Any substantial or systematic reproduction, redistribution, reselling, loan,
sub-licensing, systematic supply, or distribution in any form to anyone is
expressly forbidden.

The publisher does not give any warranty express or implied or make any
representation that the contents will be complete or accurate or up to
date. The accuracy of any instructions, formulae, and drug doses should be
independently verified with primary sources. The publisher shall not be liable
for any loss, actions, claims, proceedings, demand, or costs or damages
whatsoever or howsoever caused arising directly or indirectly in connection
with or arising out of the use of this material.